Monitor for follow-up Form 4 filings confirming actual sale execution. If completed, the sale could create short-term price pressure, but given the stock's strong analyst consensus (94% bullish) and recent positive momentum, the impact is likely limited. Watch for any additional insider or affiliate selling patterns.
Price Chart
Executive Summary
OrbiMed Advisors LLC, a major healthcare investment firm and significant shareholder in Enliven Therapeutics, filed a Form 144 notice of intent to sell 272,322 shares of common stock, valued at approximately $11.5 million based on the filing. The shares were acquired via merger in February 2023. While the sale has not yet been executed, the filing signals that a large holder is considering reducing its position, creating modest near-term overhang.
Key Facts
- OrbiMed Advisors LLC filed Form 144 on June 15, 2026, indicating intent to sell 272,322 shares of ELVN common stock.
- Estimated market value of proposed sale: $11,535,559.92 (based on filing data).
- Shares were originally acquired on February 23, 2023 via merger (IMARA Inc.).
- OrbiMed is a major institutional holder; the proposed sale represents approximately 0.4% of ELVN's outstanding shares.
- Recent insider activity (30 days) includes 2 sells totaling $404K, but this filing is significantly larger.
Financial Impact
Potential selling pressure of ~$11.5 million, or ~0.4% of market cap, if the sale is executed.
Risk Factors
- OrbiMed may execute the sale, adding supply to the market and potentially depressing the stock price.
- The filing signals reduced conviction from a key institutional holder, which could weigh on sentiment.
- Further selling by other insiders or affiliates could amplify the overhang.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0000947871-26-000628 |
| Document: 0000947871-26-000628-index.html | 0000947871-26-000628 |
| Document: 0000947871-26-000628.txt | 0000947871-26-000628 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Insider Cluster | $41.93 | awaiting T+5 | — | $41.49 (−1.05%) |
Oct 19, 2026 7d ago | 144 | $41.25 | awaiting T+5 | — | $41.49 (+0.58%) |
Oct 16, 2026 10d ago | 3 | $38.70 $41.49 | ▲ +7.21% | ▲ +7.35% | $41.49 (+7.21%) |
Oct 14, 2026 12d ago | 8-K | $39.33 $41.93 | ▲ +6.61% | ▲ +7.63% | $41.49 (+5.49%) |
Sep 21, 2026 5w ago | Insider Cluster | $48.19 $46.51 | ▼ −3.49% | ▼ −2.30% | $41.49 (−13.90%) |
Sep 4, 2026 7w ago | 144 | $59.32 $54.43 | ▼ −8.24% | ▼ −7.03% | $41.49 (−30.06%) |
Aug 19, 2026 9w ago | Insider Cluster | $58.97 $60.50 | ▲ +2.59% | ▲ +1.48% | $41.49 (−29.64%) |
Aug 9, 2026 11w ago | Institutional Cluster | $59.42 $59.54 | ▲ +0.19% | ▲ +0.24% | $41.49 (−30.18%) |
Jul 21, 2026 13w ago | Insider Cluster | $52.85 $52.97 | ▲ +0.23% | ▲ +2.63% | $41.49 (−21.49%) |
Jun 22, 2026 17w ago | 144 | $48.60 $50.85 | ▲ +4.63% | ▲ +3.62% | $41.49 (−14.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers